Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.

about

Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.

Item

http://www.wikidata.org/entity/Q47149685

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Nilotinib dose-optimization in ...... final results from ENESTxtnd.

@en

Nilotinib dose-optimization in ...... final results from ENESTxtnd.

@nl

type

Item

label

Nilotinib dose-optimization in ...... final results from ENESTxtnd.

@en

Nilotinib dose-optimization in ...... final results from ENESTxtnd.

@nl

prefLabel

Nilotinib dose-optimization in ...... final results from ENESTxtnd.

@en

Nilotinib dose-optimization in ...... final results from ENESTxtnd.

@nl

P1476

Nilotinib dose-optimization in ...... : final results from ENESTxtnd

@en

P2093

Alaa Elhaddad

http://www.w3.org/2001/XMLSchema#string

Anna G Turkina

http://www.w3.org/2001/XMLSchema#string

Carolina Pavlovsky

http://www.w3.org/2001/XMLSchema#string

Darshan Dalal

http://www.w3.org/2001/XMLSchema#string

Eduardo Munhoz

http://www.w3.org/2001/XMLSchema#string

Hang Quach

http://www.w3.org/2001/XMLSchema#string

Jake Shortt

http://www.w3.org/2001/XMLSchema#string

Jeffrey H Lipton

http://www.w3.org/2001/XMLSchema#string

Lee-Yung Shih

http://www.w3.org/2001/XMLSchema#string

Luis Meillon

http://www.w3.org/2001/XMLSchema#string

P2860

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

P304

219-228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14829

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

179

http://www.w3.org/2001/XMLSchema#string

P50

Timothy Hughes

V J Louw

P577

2017-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28699641

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

5655928

http://www.w3.org/2001/XMLSchema#string